SECOND-GENERATION TYROSINE KINASE INHIBITORS (TKI) AS SALVAGE THERAPY FOR RESISTANT OR INTOLERANT PATIENTS TO PRIOR TKIs. Mediterr J Hematol Infect Dis [Internet]. 2014 Jan. 2 [cited 2026 Apr. 18];6(1):e2014003. Available from: https://www.mjhid.org/mjhid/article/view/2014.003